Literature DB >> 7690419

The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein.

M Conrad1, V J Bubb, R Schlegel.   

Abstract

The human papillomavirus (HPV) E5 proteins are predicted from DNA sequence analysis to be small hydrophobic molecules, and the HPV type 6 (HPV-6) and HPV-11 E5 proteins share several structural similarities with the bovine papillomavirus type 1 (BPV-1) E5 protein. Also similar to the BPV-1 E5 protein, the HPV-6 and HPV-16 E5 proteins exhibit transforming activity when assayed on NIH 3T3 and C127 cells. In this study, we expressed epitope-tagged E5 proteins from both the "low-risk" HPV-6 and the "high-risk" HPV-16 in order to permit their immunologic identification and biochemical characterization. While the HPV-6 and HPV-16 E5 proteins fail to form disulfide-linked dimers and oligomers, they did resemble the BPV-1 E5 protein in their intracellular localization to the Golgi apparatus, endoplasmic reticulum, and nuclear membranes. In addition, the HPV E5 proteins also bound to the 16-kDa pore-forming protein component of the vacuolar ATPase, a known characteristic of the BPV-1 E5 protein. These studies reveal a common intramembrane localization and potential cellular protein target for both the BPV and HPV E5 proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690419      PMCID: PMC238039     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  The evolution of H+-ATPases.

Authors:  N Nelson; L Taiz
Journal:  Trends Biochem Sci       Date:  1989-03       Impact factor: 13.807

2.  Membrane protein association by potential intramembrane charge pairs.

Authors:  P Cosson; S P Lankford; J S Bonifacino; R D Klausner
Journal:  Nature       Date:  1991-05-30       Impact factor: 49.962

3.  Disruption of genes encoding subunits of yeast vacuolar H(+)-ATPase causes conditional lethality.

Authors:  H Nelson; N Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

4.  Transforming activity of a 16-amino-acid segment of the bovine papillomavirus E5 protein linked to random sequences of hydrophobic amino acids.

Authors:  B H Horwitz; D L Weinstat; D DiMaio
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  Papillomaviruses in human cancers.

Authors:  H Zur Hausen
Journal:  Mol Carcinog       Date:  1988       Impact factor: 4.784

6.  Transforming activity of E5a protein of human papillomavirus type 6 in NIH 3T3 and C127 cells.

Authors:  S L Chen; P Mounts
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

7.  Distribution and specific identification of papillomavirus major capsid protein epitopes by immunocytochemistry and epitope scanning of synthetic peptides.

Authors:  P S Lim; A B Jenson; L Cowsert; Y Nakai; L Y Lim; X W Jin; J P Sundberg
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

8.  Use of anticontamination primers in the polymerase chain reaction for the detection of human papilloma virus genotypes in cervical scrapes and biopsies.

Authors:  A J van den Brule; E C Claas; M du Maine; W J Melchers; T Helmerhorst; W G Quint; J Lindeman; C J Meijer; J M Walboomers
Journal:  J Med Virol       Date:  1989-09       Impact factor: 2.327

9.  Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein.

Authors:  L Petti; L A Nilson; D DiMaio
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

10.  The E5 oncoprotein of bovine papillomavirus binds to a 16 kd cellular protein.

Authors:  D J Goldstein; R Schlegel
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

View more
  69 in total

1.  Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.

Authors:  Frauke Fehrmann; David J Klumpp; Laimonis A Laimins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 2.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

3.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

4.  A role for HPV16 E5 in cervical carcinogenesis.

Authors:  John P Maufort; Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

5.  The canine papillomavirus e5 protein signals from the endoplasmic reticulum.

Authors:  Rachel Condjella; Xuefeng Liu; Frank Suprynowicz; Hang Yuan; Sawali Sudarshan; Yuhai Dai; Richard Schlegel
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

6.  Membrane orientation of the human papillomavirus type 16 E5 oncoprotein.

Authors:  Ewa Krawczyk; Frank A Suprynowicz; Sawali R Sudarshan; Richard Schlegel
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

Review 7.  Roles of regulated intramembrane proteolysis in virus infection and antiviral immunity.

Authors:  Jin Ye
Journal:  Biochim Biophys Acta       Date:  2013-12

8.  Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein.

Authors:  Ewa Krawczyk; John A Hanover; Richard Schlegel; Frank A Suprynowicz
Journal:  Biochem Biophys Res Commun       Date:  2008-05-01       Impact factor: 3.575

Review 9.  The bovine papillomavirus E5 protein and the PDGF beta receptor: it takes two to tango.

Authors:  Kristina Talbert-Slagle; Daniel DiMaio
Journal:  Virology       Date:  2008-11-06       Impact factor: 3.616

10.  Mutational analysis of human papillomavirus type 11 E5a oncoprotein.

Authors:  S L Chen; T Z Tsai; C P Han; Y P Tsao
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.